Scholarlink

<p>Interleukin-1 receptor-associated kinase 4 (IRAK4) is a key mediator of MYD88^L265P-driven diffuse large B-cell lymphoma (DLBCL) and a promising drug target. We applied an integrated in silico pipeline, namely, 2D-QSAR (MLR with GA), molecular docking, ADMET profiling, and 100-ns molecular dynamics, to prioritize pyrrolopyrimidine-based IRAK4 inhibitors. The final 2D-QSAR model achieved R² = 0.7279, Q²_LOO = 0.5982, and CCC = 0.7748 and showed good external predictability (RMSE_test = 0.4441, CCC_test = 0.6934). Docking identified compound 15 (− 10.1&#xa0;kcal·mol⁻¹) and its optimized analogue 15c (− 10.3&#xa0;kcal·mol⁻¹) as the top binders. Compound 15c exhibited strong binding (MM-GBSA ΔG_bind = − 66.41&#xa0;kcal·mol⁻¹ vs. − 57.86&#xa0;kcal·mol⁻¹ for ND-2158), high predicted intestinal absorption (~ 91.6%), and AMES-negative status; 100-ns MD confirmed a stable binding pose. While experimental validation is needed, compound 15c is prioritized as a promising lead for MYD88-mutant DLBCL.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Integrated QSAR, docking, pharmacokinetics, and molecular dynamics approaches for designing IRAK4 inhibitors against MYD88^L265P-driven diffuse large B-cell lymphoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月11日

查看全文
  • Josiah Joseph Isah,
  • Adamu Uzairu,
  • Sani Uba,
  • Muhammad Tukur Ibrahim

摘要

Interleukin-1 receptor-associated kinase 4 (IRAK4) is a key mediator of MYD88^L265P-driven diffuse large B-cell lymphoma (DLBCL) and a promising drug target. We applied an integrated in silico pipeline, namely, 2D-QSAR (MLR with GA), molecular docking, ADMET profiling, and 100-ns molecular dynamics, to prioritize pyrrolopyrimidine-based IRAK4 inhibitors. The final 2D-QSAR model achieved R² = 0.7279, Q²_LOO = 0.5982, and CCC = 0.7748 and showed good external predictability (RMSE_test = 0.4441, CCC_test = 0.6934). Docking identified compound 15 (− 10.1 kcal·mol⁻¹) and its optimized analogue 15c (− 10.3 kcal·mol⁻¹) as the top binders. Compound 15c exhibited strong binding (MM-GBSA ΔG_bind = − 66.41 kcal·mol⁻¹ vs. − 57.86 kcal·mol⁻¹ for ND-2158), high predicted intestinal absorption (~ 91.6%), and AMES-negative status; 100-ns MD confirmed a stable binding pose. While experimental validation is needed, compound 15c is prioritized as a promising lead for MYD88-mutant DLBCL.

Graphical abstract